Our Journey

Why Coriolis
Our Journey
The Coriolis Effect Our Facilities Leadership Team Careers

Coriolis Pharma has grown from a pioneering academic spinout of the Ludwig-Maximilians University (LMU) Munich to a leading force in the biologics industry. Our journey has been driven by innovation, expansion and a relentless commitment to advancing biologics development. Explore our milestones, which reflect our growth and demonstrate our dedication to being a trusted partner and expert in drug product development within the dynamic world of biologics, gene, and cell therapies.

Milestones

2024: Establishment of U.S. Business Entity

By establishing Coriolis Pharma U.S. Inc., we expanded our global footprint, enhancing our ability to serve clients in North America more efficiently and with faster access to our scientific expertise.

This strategic move also supported the launch of our innovative Accelerator Programs, designed to fast-track drug product development from early-stage research to phase I clinical trial readiness.

2022: Expansion for ATMP Development

In response to the emerging advanced therapy medicinal products (ATMPs) field, we expanded into incremental new facilities equipped to handle up to biosafety level 2. This investment positioned us at the forefront of ATMP development, supporting gene and cell therapy innovations with formulation development, cell culture activities, particle characterization and identification, analytical ultracentrifugation and lyophilization process development.

2017: New Facilities in Martinsried

Our move to our property of around 4.000 sqm in Martinsried, near our founding site, increased our operational capacity and met the constantly growing demand for our formulation and analytical services.

The new facilities provided us with ideal conditions for sustainable growth and the expansion of our services over the following years.

2017: Biosafety Level 2 Certification

With the addition of a biosafety level (BSL) 2 certification, we enhanced our capabilities to handle a broader range of biologics, including gene and cell therapy products and viral vectors. This expansion was crucial in meeting the evolving needs of the market and our clients.

2012: GMP Accreditation

Achieving good manufacturing practice (GMP) accreditation marked a significant milestone. It allowed us to expand our services to include comprehensive GMP analytics, particularly for innovative and complex methods, solidifying our reputation for quality and compliance with a scientific background.

With this GMP accreditation, we also laid the foundation for our current status as a provider of comprehensive and high-quality development and analytical services along the entire value chain from preclinical to commercialization.

2009: Move to the IZB in Martinsried

We moved to the Innovations- und Gründerzentrum Biotechnologie (IZB), a biotech incubator with a high reputation in Martinsried near Munich, to support our growing team and capabilities, fostering a collaborative environment that enhanced our research and development efforts.

We started with two labs and two offices on about 80 square meters and grew to more than 900 sqm and 65 employees within the next eight years.

2008: Foundation of Coriolis Pharma

Four founders established Coriolis Pharma: Dr. Michael Wiggenhorn, Dr. Andrea Hawe, Dr. Frank Schaubhut and Thomas Wiggenhorn, supported by Prof. Dr. Wolfgang Frieß (LMU) and Prof. Dr. Gerhard Winter (LMU), who continue to act as Scientific Advisors.

From the very beginning, our goal was to offer scientific expertise and innovative formulation services for biologics—a niche that was not commonly addressed by other contract research and development organizations (CRDOs) at the time.

Navigating the Biologics Landscape

Throughout our history, Coriolis Pharma has adapted to the rapidly changing biologics market, consistently staying ahead of industry trends and technological advancements. From our early days of pioneering formulation services to our current role as a comprehensive partner in biologics development, we have continually evolved to meet the needs of our clients.

Our expertise in early-stage formulation, robust analytical support under R&D and GMP and advanced manufacturing solutions enable to tackle complex challenges and accelerate drug development. As we look to the future, we remain dedicated to leveraging our scientific prowess and innovative spirit to lead biologics and ATMP development.

 

Explore More with Coriolis

Talk to Our Experts or Request a Quote

Our expert team is ready to answer your questions and guide you to the services best suited to your program’s modality, stage and challenge. If your needs are well-defined, we’ll begin the quotation process.

Description